Telemonitoring Platforms and Chemotherapy-Associated Toxicity

Summary

The primary objective of this trial is to evaluate the impact of a telemonitoring platform on patient satisfaction with care amongst adult cancer patients receiving chemotherapy. The key questions it seeks to address revolve around the potential improvements in both quality of life and satisfaction with healthcare. Participants in the trial will be provided with a specialized application developed by a team of experienced oncology professionals. Their quality of life and healthcare experience will be compared with that of the control group, who will only receive the standard in-person check-ups established by their healthcare team.

Eligibility

Inclusion Criteria:

* Adult patients (\>18 years)
* Histologically confirmed diagnosis of lung, gastric, gallbladder, colon, breast, or cervical carcinoma in any of its forms and stages
* Initiating an outpatient curative intent chemotherapy regimen within the facilities of UC-Christus Health Network or Hospital Sotero del Río during the months of November 2023 to July 2024
* Proficient in the Spanish language
* Possess a smartphone, regardless of the native operating system (iOS® or Android®)

Exclusion Criteria:

* Individuals undergoing concomitant radiotherapy
* Those with any form of sensory impairment hindering the use of the application
* Those with cognitive impairment or psychiatric pathology preventing the use of the application
* Those who do not wish to participate in the study

Conditions2

Browse More Trials